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ABSTRACT
Objectives: To estimate: 1) rotavirus disease burden in New Zealand
children aged under 5 years, and 2) health beneﬁts, budget impact, and
cost-effectiveness of incorporating a pentavalent rotavirus vaccine (PRV)
into the national immunization schedule.
Methods: A static equilibrium model was developed to evaluate health
beneﬁts and budget impact of vaccinating ﬁve successive birth cohorts
with PRV at $50 per dose and 85% coverage (three doses). Cost-
effectiveness was estimated from the societal perspective in year 5 of the
program, with future health beneﬁts discounted at 3.5% per annum.
Results: By the age of 5 years, one in ﬁve children will have sought
medical advice for rotavirus gastroenteritis and one in 43 will have
been hospitalized. In 2009, we estimate 1506 hospitalizations (476 per
100,000; 95% conﬁdence interval 451, 502), 3086 Emergency Depart-
ment (ED) presentations not requiring hospitalization, plus 10,120 cases
of rotavirus gastroenteritis managed solely in primary care. The annual
societal cost is $7.07 million, including 41% from hospitalization and
25% from caregiver income loss. Health beneﬁts will increase and the cost
of illness will decline by 78% in year 5 as successive birth cohorts are
immunized. In the ﬁfth year, 1191 hospitalizations, 2442 ED treated cases,
9762 primary care consultations, and 0.8 deaths will be averted. It
requires six vaccinated children to avoid one primary care consultation, 49
to avert one hospitalization, and 73,357 to prevent one death. The incre-
mental cost is $2.99 million and the break-even price per vaccine dose is
$32.39 at 2006 prices. The cost is $2509 to avert one hospitalization and
$305 to prevent one case seeking health-care assistance. The cost per
life-year gained in year 5 is $143,097 and the cost per quality-adjusted
life-year (QALY) gained is $46,092 (US$26,774). The cost per QALY is
sensitive to incidence rates, vaccine price and efﬁcacy, loss of quality of life
by the child, case fatality, and caregiver income loss.
Conclusions: From a societal perspective, addition of PRV to the New
Zealand childhood immunization schedule would confer important clini-
cal gains at a modest cost per QALY gained.
Keywords: cost-effectiveness, gastroenteritis, immunization, rotavirus,
vaccine.
Introduction
Rotaviruses are the most common cause of severe gastroenteritis
in infants and young children worldwide. Virtually all children
are infected by the age of 5 years. Annually, rotaviruses cause 114
million episodes of diarrhea, 25 million clinic visits, 2.4 million
hospital admissions, and more than 500,000 deaths in children
up to age 5 years [1,2]. Although most deaths are in developing
countries, every year, more than 220,000 children living in indus-
trialized countries are hospitalized because of rotavirus gastro-
enteritis [1,3]. This includes 60,000 children hospitalized in the
United States [4], 87,000 in the European Union [5], and 10,000
in Australia [6]. Within these industrialized countries, for every
10 children admitted to hospital with rotavirus gastroenteritis,
between 6 and 20 are treated and discharged from the Emergency
Department (ED) [7,8] and 50 to 100 are managed solely in
primary health care [3,7,8]. Furthermore, in countries with tem-
perate climates, rotavirus epidemics every winter and spring
coincide with peak respiratory virus activity, placing further pres-
sure on health-care facilities, including hospitals where elective
surgery may be canceled and overcrowding increases the risk of
nosocomial infections [9]. The annual health and society-related
costs in the United States from rotavirus gastroenteritis is esti-
mated at $US1 billion dollars [10], in the European Union, the
cost is €550 million [11] and, in Australia, direct medical costs
are estimated at $26 million [7].
Although improvements in sanitation, personal hygiene,
food, and water quality have resulted in substantial health ben-
eﬁts, rates of rotavirus disease remain substantially the same in
both industrialized and developing countries [1,10]. Conse-
quently, rotavirus vaccines are seen as the only public health
intervention capable of controlling rotavirus disease. Two
licensed oral vaccines have recently shown 85% to 96% efﬁcacy
against severe rotavirus gastroenteritis leading to hospitalization
or ED attendance in trials conducted in Europe and the
Americas [12,13]. One vaccine contains RIX4414, a single live
attenuated human P1A [8] G1 strain (Rotarix; GlaxoSmith-
Kline, Rixensart, Belgium). The other is a live naturally attenu-
ated pentavalent bovine-human reassortant vaccine containing
the four most common human G serotypes (G1-G4) and the
most common human P serotype (P1A [8]) worldwide (pentava-
lent rotavirus vaccine [PRV] or RotaTeq; Merck and Co, White-
horse Station, NJ). Although the two vaccines differ in their
strain composition, both seem to provide protection against a
variety of strains, including those not included in the vaccine.
Moreover, the vaccines are well tolerated and do not appear to
be associated with intussusception, a rare complication found
previously in recipients of RotaShield, the ﬁrst ever licensed
rotavirus vaccine [12–14]. Rotavirus vaccines are now licensed
in more than 100 countries and they have been incorporated
into the national childhood immunization programs of 10 coun-
tries from Europe and Latin America, the United States, and
Australia.
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As other countries decide upon introducing rotavirus vaccines
into their immunization programs, many will undertake an eco-
nomic evaluation of these vaccines. This is because of large
differences in hospitalization incidence rates and costs between
countries, including even neighboring regions [1,8,15]. Such
variations may result from differences in primary care access,
referral patterns, disease management, hospital admission poli-
cies, unit costs, and accuracy of diagnostic coding practices.
Because the annual cost of rotavirus gastroenteritis in New
Zealand and the impact of immunization are unknown, the
present study estimates the current burden of rotavirus gastro-
enteritis in New Zealand and the annual health beneﬁts, budget
impact, and cost-effectiveness of including PRV in the national
childhood immunization schedule. A catch-up program was not
included as there are insufﬁcient safety and efﬁcacy data in
infants older than 32 weeks of age to allow authorities to make
such a recommendation.
The primary measures of cost-effectiveness are the cost per
life-year gained and the cost per quality-adjusted life-year
(QALY) gained in year 5 of a 5-year universal vaccination
program for successive birth cohorts. At this stage, incidence
rates will have stabilized at a new level because there are few
cases of serious rotavirus gastroenteritis in children older than
5 years of age [16]. Secondary measures are the cost per
case averted and the cost per hospital admission averted. The
analysis takes into account consecutively the societal, health-
care (Government plus patient) and Government (Ministry of
Health and Pharmaceutical Management Agency [PHARMAC])
perspectives.
Methods
Disease Burden
National public hospital discharge data from the New Zealand
Health Information Service (NZHIS) between July 1, 2003 and
June 30, 2006 were reviewed to identify children less than 5 years
of age with a primary diagnosis of acute gastroenteritis as cat-
egorized by the International Classiﬁcation of Diseases, 10th
revision, Australian modiﬁcation (ICD-10-AM), codes A00-A09
and K52.9 for infectious diarrhea of known and unknown
origins. There were 10,382 admissions including 391 readmis-
sions (3.8%) within 7 days. The latter were excluded from inci-
dence calculations, but included in cost burden estimates,
because these readmissions will most likely have resulted from
ongoing complications from the original illness or nosocomial
acquisition of another enteric agent while in the hospital. Mor-
tality from acute gastroenteritis in the period 2002 to 2003 was
also obtained from NZHIS [17].
Incidence rates for rotavirus gastroenteritis in children less
than 3 years of age were estimated by applying age and season-
adjusted proportions of rotavirus [18] to national hospitalization
rates for acute gastroenteritis. As rotavirus proportions were
unavailable for New Zealand children more than 3 years of age,
the proportion of severe rotavirus gastroenteritis at 4 and 5 years
of age was estimated as the seasonally adjusted mean of that at 2
and 3 years of age, which was stable at 0.45. Because only 14% of
admissions for all cases of gastroenteritis inNewZealand children
less than 5 years of age occur after 3 years of age, this parameter
has a relatively minor impact on the outcome of the analysis (see
Results). We also assumed conservatively that the incidence of
rotavirus gastroenteritis is zero beyond 5 years of age. The longest
and largest study of hospitalized children with gastroenteritis was
reported from Melbourne, Australia [19]. In this 13-year study,
97% of rotavirus hospital admissions were in children less than 5
years of age. Cases of acute rotavirus gastroenteritis over the
period 2009 to 2019 were then estimated for children less than 5
years of age, based on the birth rate in the period July 2007 to June
2008 (64,140) assumed to be stable for 10 years and adjusted for
all-cause mortality as the cohort matures [17].
Immunization
Immunization with PRV reduces rotavirus disease, resulting in
either an ED presentation or hospital admission by 94% and
96%, respectively, but this degree of efﬁcacy is not achieved until
2 weeks after the ﬁnal dose is taken at 5 months of age [12].
Nevertheless, the NZHIS national public hospital discharge data
showed that, on average, 80% of gastroenteritis admissions
during infancy occurred in the second 6 months of life when 85%
of children would be fully immunized with PRV if it were taken
on schedule at the coverage rate for the recently discontinued
oral polio vaccine [20]. Therefore, the two halves of the ﬁrst year
were analyzed separately, with adjustment in the ﬁrst half of the
year for the amount of time during which infants are vaccinated
with one, two, or three doses according to the New Zealand
immunization schedule.
Because fecal samples are collected infrequently from ED cases
that are not admitted to the hospital, and because there is no
national database of ED presentations, the incidence of ED pre-
sentations of rotavirus gastroenteritis was estimated from rotavi-
rus hospitalizations by applying the ratio of “EDpresentations” to
“hospitalizations” for intestinal infectious diseases (ICD10 A00
to A09 and K52.9) at Middlemore Hospital in South Auckland
(2.05). This ratio is very similar to that for rotavirus gastroenteri-
tis in Australia (2.22) [7] and England andWales (2.08) [21]. This
ratio was varied by 30% in sensitivity analyses.
Similarly, because the incidence of primary health-care cases
of rotavirus gastroenteritis is not available, this was estimated
from the mean of the ratio of rotavirus gastroenteritis primary
health-care consultations to hospitalizations from British [21]
and Australian [7] studies adjusted for referrals to hospital,
assuming that 70% of hospital cases are referred by a general
practitioner (GP) [22]. The British and Australian ratios (4.2 and
9.3, respectively) were used as limits in sensitivity analysis. The
large phase III randomized clinical trial of PRV also reported that
“nonurgent” consultations in the placebo group outnumbered
admissions sevenfold [12]. The percentage of hospital cases
referred by GPs was also varied in sensitivity analysis.
Budget Impact of PRV Immunization Program
When a novel vaccine is introduced into the childhood immuni-
zation schedule, it remains there for at least 5 years and generally
longer. Government decision-makers need to know the budget
impact during its introduction and its cost-effectiveness after an
introductory period of time has passed, taking into account all
associated costs and health beneﬁts. We therefore developed a
spreadsheet static equilibrium economic model to show the ben-
eﬁts, costs, budget impact, and cost-effectiveness of vaccinating
successive New Zealand birth cohorts for 5 years, commencing
in 2010. In the ﬁrst year, the impact of immunization is limited to
the birth cohort, then by year 5, protection extends to most
children less than 5 years of age as the cohort ages, assuming that
PRV maintains its effectiveness.
Adverse events are not included in the model because com-
bined safety data from 71,799 subjects recruited into the 3 phase
III trials showed PRV to be safe and well tolerated [23]. In
particular, there is no increased risk of intussusception or clus-
tering of cases after immunization [14,24]. Costs and health
beneﬁts were evaluated over a 10-year time horizon. This period
was chosen because the incidence rate for severe gastroenteritis is
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much lower in children 5 years of age and over and, conse-
quently, the impact of 5 years of vaccination of successive birth
cohorts is almost complete after 10 years. Work loss by the
caregiver was estimated from UK data in the large randomized
clinical trial, Rotavirus Gastroenteritis Epidemiology and Viral
Types in Europe Accounting for Losses in Public Health and
Society (REVEAL) [22].
Cost-effectiveness
The cost-effectiveness of infant immunization was obtained in
year 5 of the program, when the number of cases averted each
year is expected to have stabilized. Traditional measures of cost-
effectiveness, such as the cost per QALY gained [25], allow
comparisons across different health-care programs but are difﬁ-
cult to capture reliably in young children because gastroenteritis,
although common and on occasions severe, is a transient illness
with low mortality in industrialized countries. Also, the cost per
QALY relies heavily on estimates of case fatality and quality of
life (health state utility), which are somewhat uncertain. There-
fore, secondary economic outcomes were also utilized.
Deaths from acute gastroenteritis are rare in New Zealand
children, being no more than one to two per year [26]. In New
Zealand, the ratio of admission rates to mortality (a measure of
case fatality) for children less than 5 years of age with gastroen-
teritis in the period 1990 to 2006 (admissions) and 1990 to 2004
(deaths) was 0.00048 [27], which is similar to that for rota-
virus gastroenteritis in France (0.000534) [28] and Australia
(0.00040) [29] but higher than in England and Wales (0.00020)
[30]. We utilized the age-speciﬁc case fatality for gastroenteritis
in New Zealand [27] and varied it by 50% in sensitivity analy-
ses. The disutility associated with an episode of gastroenteritis in
a child and their caregiver was taken from a recent Canadian
study [31]. Based on UK consultation patterns for gastroenteritis,
this translates to a QALY loss of 0.00220 per episode for a child
and 0.00184 for a caregiver [32]. This parameter was also varied
by 50% in sensitivity analyses. The impact of including disutil-
ity for two caregivers was also estimated in a sensitivity analysis
for comparison with other studies [29,32].
Life-years gained by universal infant immunization were esti-
mated as deaths averted multiplied by life expectancy from New
Zealand life tables (Statistics NZ), discounted to present value at
3.5% per annum. The QALYs gained by universal immunization
were obtained by adding the discounted life-years gained to the
utility gained by child and caregiver(s) by averting rotavirus
admissions, ED presentations, and GP cases. Secondary out-
comes were the cost required to avert one GP consultation or
hospital admission for rotavirus gastroenteritis in year 5 of the
program.
Vaccine Administration and Coverage
If PRV is introduced into the national immunization schedule, it
will be made available to each birth cohort where it can be safely
administered with other vaccines at 6 weeks, 3 months, and 5
months of age [10,24,33]. Uptake of the ﬁrst, second, and third
doses of PRV is assumed to be the same as that reported by the
latest national immunization coverage survey based on uptake of
the recently discontinued oral polio vaccine in three doses at the
same ages (91%, 89%, and 85%, respectively [20,33]). We
assumed that coverage at these levels would be achieved on
schedule by each successive birth cohort for 5 years.
Vaccine Efﬁcacy
The phase III PRV efﬁcacy trial reported that rotavirus gastroen-
teritis of any severity and severe rotavirus disease were reduced
by 74% and 98%, respectively [12]. Nonurgent medical visits
were reduced by 86%, ED consultations by 93.7%, and hospi-
talizations for rotavirus gastroenteritis by 95.8%. We assumed
protective efﬁcacy of 83%, 81%, and 95% for reducing hospi-
talizations and ED visits after doses 1, 2, and 3, respectively [24],
and proportionally lower efﬁcacy for reducing GP consultations
(75%, 73%, and 86%, respectively). Vaccine effectiveness in the
ﬁrst year of life was adjusted for the expected coverage by age, in
months.
The Finnish Extension Study involving 20,736 subjects
enrolled in the pivotal phase III trial reported that protective
efﬁcacy against severe rotavirus disease requiring ED presenta-
tion or hospital admission remained at 94% (95% conﬁdence
interval [CI] 91, 96) for up to 3.1 years after receiving the third
dose, by which time there was a marked reduction in rotavirus
cases seeking hospital-based care [34]. In the base-case analysis,
we assumed that PRV protective efﬁcacy remains stable for 5
years. In a sensitivity analysis, we investigated the impact of a
5% annual decline in protection in years 3 to 5. It is not neces-
sary to make assumptions about vaccine efﬁcacy beyond 5 years
because of the low incident rate for rotavirus gastroenteritis after
5 years of age [19].
Direct Medical Costs
For societal and health-care perspectives, our analysis utilized the
mean cost (weighted by the annual numbers of acute gastroen-
teritis admissions in the corresponding hospitals) of consecutive
hospitalizations for children less than 5 years of age with a
principal diagnosis of rotavirus gastroenteritis (ICD10 A080) at
four of New Zealand’s largest hospitals (Middlemore, Waikato,
Wellington, and Christchurch), all of which utilized patient-level
costing systems. The weighted mean hospitalization cost across
these four centers for 350 admissions (including one admission to
an intensive care unit) was $1889 (95% CI $1709, $1990). Mean
hospitalization costs to the Government were calculated using
diagnosis-related group (DRG) cost weights for 2398 consecutive
cases of rotavirus gastroenteritis (ICD10 A080) in the period July
2003 to June 2006 (NZHIS) multiplied by the national price for
2006/2007 ($3151).
Often, children with gastroenteritis presenting to the ED are
not admitted to the hospital and few of these have their feces
collected, so the causative agent is usually unknown. We esti-
mated the unit cost from 208 consecutive nonhospitalized ED
presentations for children aged less than 5 years with a principal
diagnosis of conﬁrmed rotavirus gastroenteritis at Middlemore
Hospital (n = 139) and Waikato Hospital (n = 69), weighted by
the annual numbers of acute gastroenteritis cases in this age
group presenting to the corresponding facility. Costs included ED
and pediatric staff and overheads. The weighted mean cost of
such presentations was $585 (95% CI $550, $620). Correspond-
ing information was unavailable from other hospitals. Neverthe-
less, for comparison, Wellington Hospital’s average price was
$486 for ED triage level 3 (attendance within 30 minutes, which
is the routine triage level for children with acute gastroenteritis).
Children who were discharged directly from the ED are pre-
scribed one box containing 10 sachets of oral rehydration solu-
tion (pharmaceutical subsidy $2.86 [35]; no copayment).
In the community, PRV is usually administered by practice
nurses and it effectively replaces an oral polio vaccine that was
withdrawn recently and replaced by an inactivated injectable
polio vaccine [33]. Most primary care practices are now capi-
tated. Because PRV is administered during the routine scheduled
immunization visits and, as an oral gel, requires minimal addi-
tional handling, there is unlikely to be additional cost or
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Government reimbursement. For GP consultations other than
immunization, the notional charge to the Government at the time
of writing is $39.70 per visit for children less than 6 years of age,
which includes a practice nurse subsidy [36]. Primary health
organizations are discouraged from charging copayments for
children less than 6 years of age. Because information was not
available and costs are relatively minor, we excluded costs of
additional diapers, pharmaceuticals, and laboratory tests, if any.
Nonmedical Costs by Informal Caregivers
The marginal cost of travel to the hospital’s ED was estimated at
$4.00 based on one 20-km return trip at $0.20 per kilometer. For
cases that were admitted to the hospital, this cost was doubled
because at least two trips are required. GP cases are likely to
incur only minor transportation costs, which were set to zero.
Indirect Costs by Informal Caregivers
The median age for women giving birth in 2005 was 30 years
(Statistics NZ). Based on the median income for female wage and
salary earners 30 to 34 years of age of $33,000 per year (Statis-
tics NZ) and 70% workforce participation [37] we estimate the
median pretax cost of work loss as $59.36 per person per day,
adjusting for weekends and holidays. Because there is no infor-
mation about work loss associated with caring for children with
gastroenteritis in New Zealand, we applied this ﬁgure to a study
from the Northwest of England showing that 91% of caregivers
took a mean of 4.0 days off work during a hospitalization for
rotavirus gastroenteritis; 54% of caregivers of children who were
treated in the ED took 2.9 days off work; and 20% of caregivers
of children treated by a GP took 7.5 days off work [22]. A study
from the United States showed a median of 2 days work loss for
caregivers of children with rotavirus gastroenteritis treated at
outpatient centers [38]. The loss of income was varied by 30%
in sensitivity analyses.
Because oral PRV would be administered alongside other
scheduled infant vaccines, we assumed that no additional time
would be lost from immunization. Home care cases that do not
come to medical attention were excluded from the analysis
because no information is available on costs or incidence rates.
This is conservative, because home care cases will contribute to
loss of quality of life, caregiver income, and nonmedical costs
such as transportation, oral rehydration solutions, additional
diapers, and child care changes [39].
Discount Rate
For cost-effectiveness analyses in year 5, a 3.5% annual discount
rate was applied to future life-years, as this is the rate used by the
national Pharmaceutical Management Agency [40]. There are no
future costs. The discount rate was varied in sensitivity analyses
from 0% to 5%. Discounting was not applied to the budget
impact analysis because it is intended as a year-by-year projection
to guide budgetary planning, not a “net present value” analysis.
Table 1 shows the input parameters for the economic model,
and their sources. Ranges for sensitivity analyses of potentially
inﬂuential variables were set using 95% CIs where available (e.g.,
efﬁcacy, incidence rate for admissions, cost of an admission) or
conservative, plausible limits.
Results
Disease Burden
The rotavirus health-care disease burden for New Zealand is
shown in Table 2 where the estimated cases and incidence rates
for rotavirus-associated hospitalization, ED presentations that
were not admitted to hospital and cases that were managed solely
by GPs for children less than 5 years of age for the 2009 calendar
year are presented. Most cases of gastroenteritis occur during
winter and spring and in the current study, 83% of cases were
captured in this period.
In the baseline year (2009), an estimated 1506 children less
than 5 years of age (incidence rate 476 per 100,000, 95% CI:
451, 502) will be admitted to hospital with rotavirus gastroen-
teritis. There will be an estimated 3086 ED presentations for
rotavirus gastroenteritis that are not hospitalized and 10,120
cases managed solely by GPs plus an unknown number of cases
that do not reach medical attention. For children less than 3 years
of age, the hospital admission rate is 661 (95% CI: 623, 700) per
100,000 (not shown), which is comparable to previous estimates
of rotavirus hospitalization rates for New Zealand children in
this age group [18]. This agreement illustrates some external
validity in methodology.
By the age of 5 years, one in ﬁve children will have consulted
a medical practitioner for rotavirus gastroenteritis and one in 43
will have been hospitalized. Based on our assumptions, about
one-quarter of children less than 5 years of age who consult a GP
for acute rotavirus gastroenteritis are referred to hospital and
one-third of these are admitted to hospital. The remainder are
treated and discharged.
Table 3 illustrates the annual cost of rotavirus gastroenteritis
in New Zealand from a societal perspective, excluding cases that
do not present to the health-care system ($7.07 million). Two-
thirds of the cost is incurred by hospital cases, including ED, and
one-quarter is the indirect cost from loss of caregiver income.
The estimated annual cost per child under 5 years of age is
$22.17.
Impact of PRV on Disease Burden
Figure 1 shows the modeled annual health beneﬁts of introducing
PRV into the national childhood immunization schedule for a
period of 5 years. Immunization of successive birth cohorts
against rotavirus becomes increasingly effective as more children
develop vaccine-induced protective immunity. The beneﬁts stabi-
lize after year 5 of the program, and then decline if PRV were to
be withdrawn (as shown). It should be noted that some patients
incur costs at each level of the health-care system (GP, ED, and
hospitalization).
In year 5 of the inclusion of PRV in the national child immu-
nization schedule, 1191 hospitalizations, 2442 ED presentations
that are not admitted to hospital, and 9762 GP consultations
would be averted (Table 4). It would require 49 children to have
up to three doses of PRV to prevent one hospitalization, and six
children vaccinated to prevent one GP consultation. Because
rotavirus gastroenteritis is seldom fatal, it would require vacci-
nation of more than one birth cohort to prevent one death.
Cost of Rotavirus Gastroenteritis
Budget impact of PRV immunization. Figure 2 demonstrates
how the annual burden of illness would change from baseline if
PRV were to be introduced into the immunization schedule for 5
years, assuming that 85% coverage (3 doses) is achieved imme-
diately. The burden of rotavirus illness from a societal perspective
reduces from $7.07 million to $1.58 million in year 5 of the
program, and would gradually increase again if PRV were to be
withdrawn. By year 5, immunization would offset $5.5 million
(78%) of the cost of rotavirus illness in that year. Including the
cost of immunization, the overall cost of illness almost doubles in
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year 1, when only children in the birth cohort develop vaccine-
induced immunity (Fig. 2). Nevertheless, in subsequent years
successively more children are protected, which reduces the
annual cost of illness. The budget impact per child would remain
stable beyond year 5 if PRV remained on the schedule because the
incidence rate is very low after this age and the beneﬁts of
immunization therefore are almost fully achieved. In practice,
coverage is likely to build up over several years, which will
reduce the annual costs and beneﬁts in parallel but have little
impact on cost-effectiveness ratios.
If PRV were incorporated into the national childhood immu-
nization schedule, the major cost drivers would be the acquisition
cost of the vaccine and the number of hospitalizations averted
due to introduction of the universal immunization program. If
the annual cost of the program remained constant (assuming
constant coverage), the annual cost of rotavirus disease would
decline as progressively more children were immunized and it
would continue to fall for as long as the protective effectiveness
of the vaccine is maintained. Nevertheless, any decrease after 5
years would be small as the incidence of rotavirus gastroenteritis
in children over 5 years of age is relatively low.
In the ﬁfth year of immunization, the incremental cost to
society is $2.99 (Table 5). The break-even acquisition vaccine
unit costs in year 5 are $32.39, $24.40, and $21.82 per dose
Table 1 Inputs to the economic model
Parameter (range) Comment/Source
Costs
Vaccine acquisition cost per dose $50 ($45–$55) Merck Sharp and Dohme NZ Ltd.
Hospital
Hospitalization $1889 ($1709, $1990) Local cost*
Hospitalization (DRG-based cost) $1512 ($1439, $1584) Mean of 2486 RVAGE admissions, 2003–2006 (NZHIS)
ED presentation $585 ($550, $620) Local cost*
GP consultations, cost to Government† $39.70 Government subsidy [36]
Caregiver daily income $59.36 Female aged 30–39 years, 70% in the workforce [37]
Subsidy for 10 sachets of oral rehydration powder (Enerlyte) $2.86 PHARMAC [35]
Caregiver loss of income
Hospitalization $245 ($172, $319) $59.36/day including 70% workforce participation
ED $105 ($74, $137)
GP $101 ($71, $131)
Transportation
Hospital admission $8.00 2 ¥ 20-km round trips at 20 c/km.
ED presentation $4.00 1 ¥ 20-km round trips at 20 c/km.
GP consultation Nil
Probabilities, rates, ratios, proportions
Vaccine efﬁcacy (three doses) Phase III trial [12,24]
Hospitalization 0.958 (0.905, 0.982)
ED presentation 0.937 (0.888, 0.965)
GP consultation 0.860 (0.739, 0.925)
Single dose (hospitalization, ED) 0.83 .
Two doses (hospitalization, ED) 0.81
Single dose (GP and work loss) 0.75 By extrapolation from phase III trial [12,24]
Two doses (GP and work loss) 0.73
Vaccination coverage‡
One dose 0.910 (0.895, 0.925) Based on oral polio vaccine uptake [20]
Two doses 0.890 (0.874, 0.906)
Three doses 0.846 (0.825, 0.867)
Incidence rate (admissions) See Table 2 Range,95% CI
Case fatality per 1000 admissions
Paediatric Society of New Zealand [27]
Age <12 months 1.37 (50%)
Age 12–23 months 0.48 (50%)
Age 24–35 months 0.56 (50%)
Age >35 months 0
Proportion ED and GP patients using oral rehydration sachets 0.5 (0.3, 0.7) REVEAL, United Kingdom data [22]
Ratio of ED presentations to hospitalizations for AGE (see Table 2) 2.05 (30%) Middlemore Hospital,Auckland
Ratio of GP consultations to hospitalizations (see Table 2) 7.8 (6,3,9.3) Mean of Australia [7] and the United Kingdom [21]
Proportion of hospital cases referred by GP 0.7 (0.5, 0.9) Estimated from UK data [22]
Vaccine decline in protection per year
Years 3–5 0 (5%) Phase III trial, second season efﬁcacy [63]
Proportion of AGE cases caused by rotavirus, age 3–4 years 0.45 (20%)
Other parameters
Birth cohorts 2009–2020 64,140 Births July 2007–June 2008 (Statistics NZ)
Time horizon 10 years
Disutility per rotavirus event
Senecal et al. [31]Child 0.0022
Caregiver(s) 0.0018
Discount rate (for life-years) 0.035 (0.0, 0.05) PHARMAC [40]
Caregiver days off work United Kingdom data [22]
Hospitalization 3.6 91% of 4 days
ED 1.6 54% of 2.9 days
GP 1.5 20% of 7.5 days
*Mean for Middlemore,Waikato,Wellington, and Christchurch Hospitals, weighted by acute gastroenteritis admissions in each hospital.
†Most general practitioners belong to capitated primary health-care organizations; this estimate is based on the notional under 6 years old medical consultation subsidy [36].
‡Because PRV is about 80% efﬁcacious with the ﬁrst dose, lower or higher compliance with the ﬁrst and second dose will have only a minor impact on cost-effectiveness.
AGE, acute gastroenteritis;CI, conﬁdence interval;DRG,diagnosis-related group;ED,Emergency Department presentations without hospitalization;GP, general practitioner;NZHIS,New Zealand
Health Information Services; PHARMAC, Pharmaceutical ManagementAgency; REVEAL, Rotavirus Gastroenteritis Epidemiology andViralTypes in EuropeAccounting for Losses in Public Health
and Society; RVAGE, rotavirus acute gastroenteritis.
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from societal, health-care, and government perspectives, respec-
tively. This cost is highest when a societal perspective is taken
because caregiver loss of income and transportation costs is
taken into account.
Cost-Effectiveness of PRV Immunization
The cost-effectiveness can be expressed in terms of future costs
and cases averted, either hospital admissions or overall. If PRV
were included in the childhood immunization schedule for 5
years, health beneﬁts would cumulate for at least 10 years, pro-
vided that protection was maintained for 5 years (Fig. 1). In year
5, in the base-case analysis from a societal perspective, the soci-
etal cost is $2509 to avert one hospitalization and $305 to avert
one GP consultation. Because gastroenteritis is seldom fatal in
New Zealand, the cost per death prevented is high.
Because decisions may entail comparing expenditure on other
programs with different time frames, in accordance with inter-
national practice, future life-years are discounted to the baseline
year [25,41]. The cost per life-year gained in year 5 is high
($143,097) because rotavirus illness is seldom fatal in New
Zealand (Table 6); however, the cost per QALY gained is modest
Table 2 Estimated annual cases in 2009 and incidence rates for rotavirus gastroenteritis in New Zealand children under 5 years of age
Cases per year Annual incidence rate per 100,000
Age (years) Hospitalizations* ED† GP‡ Total§ Hospitalizations ED GP Total
<1 466 956 3,135 4,557 727 1,491 4,887 7,105
1–2 549 1,125 3,690 5,364 861 1,765 5,788 8,414
2–3 253 519 1,703 2,476 398 815 2,673 3,885
3–4 143 292 958 1,393 224 459 1,504 2,186
4–5 94 193 634 922 148 304 996 1,448
<5 years 1,506 3,086 10,120 14,712 476 977 3,202 4,655
5 years risk 1:43 1:21 1:7 1:5
*Based on the acute incident gastroenteritis hospitalizations for July 2003 to June 2006 (NZ Health Information Services) and proportions of rotavirus by age and season.
†Estimated from the ratio of ED presentations (not admitted) to hospitalizations for acute gastroenteritis at Middlemore Hospital (2.05).
‡Estimated from the mean of the ratios of GP consultations to hospitalizations in the United Kingdom and Australia [7,21] adjusted for referrals.
§Some totals do not equal the sum of the stated components because of rounding errors.
ED, Emergency Department presentations without hospitalization; GP, general practitioner consultations without referral to hospital.
Table 3 Estimated cost to New Zealand society in 2009 of rotavirus
gastroenteritis for children less than 5 years of age, without a program of
rotavirus immunization
Cost to
New Zealand
($M)
Cost per
child under
5 years ($)
Cost
distribution
(%)
Hospitalization 2.89 9.07 40.9%
ED visits, not hospitalized 1.81 5.66 25.5%
Caregiver income 1.80 5.64 25.4%
GP visits, Government
reimbursement*
0.53 1.66 7.5%
Transportation to hospital 0.02 0.08 0.3%
Subsidy on ORT 0.02 0.06 0.3%
Total 7.07 22.17 100.0%
*Includes visits managed solely by GPs plus referred cases; patient copayment is zero for
preschool children.
ED, Emergency Department; GP, general practitioner; ORT, oral rehydration therapy
(Enerlyte).
Figure 1 Estimated annual health beneﬁts (cases averted) over a 10-year
period from including a pentavalent rotavirus vaccine (PRV) in the New Zealand
immunization schedule for 5 years. Emergency Department (ED-only) cases are
those that are not hospitalized and general practitioner (GP-only) cases are
those that are not referred to hospital.
Table 4 Estimated rotavirus cases in year 5 of inclusion of pentavalent
rotavirus vaccine (PRV) in the childhood immunization schedule compared
with exclusion*
No PRV PRV Events averted NNV
Hospitalizations 1,506 314 1,191 49
ED presentations 3,086 644 2,442 24
GP consultations† 13,335 3,543 9,792 6
Deaths 1.0 0.2 0.8 73,357
*Assumes 84.6% uptake (three doses); no discounting.
†Includes 2543 cases referred by a GP to hospital.
ED, Emergency Department; GP, general practitioner; NNV, number of children needing to
be vaccinated each year to prevent a single health-care encounter of the type speciﬁed.
Figure 2 Projected annual costs to New Zealand over 10 years, if a pentava-
lent rotavirus vaccine were to be included in the national childhood Immuni-
zation schedule for 5 years (undiscounted). ED, Emergency Department; GP,
general practitioner, ORT, oral rehydration therapy.
Rotavirus Vaccine Cost-Effectiveness 893
at $46,092 ($US26,774). The cost-effectiveness ratios are lower
(more favorable) from a societal perspective than a health-care or
government perspective because of the inﬂuence of caregiver
work loss. These ratios will improve slightly (i.e., decrease) in
subsequent years as the birth cohorts mature, provided protec-
tion is maintained. Nevertheless, any improvement is probably
modest because the incidence of severe rotavirus gastroenteritis is
very low in school-age children.
Uncertainty
The cost per QALY varies from base case over the range -36% to
+39% with realistic changes in input variables, assuming utility
loss for just one caregiver. The strongest determinants of vari-
ability are: the rates of hospital admissions, GP consultations,
and ED presentations; caregiver income loss per case; vaccine
unit price; efﬁcacy; case fatality; and the transient loss of quality
of life by the child and caregiver (Fig. 3). It is relatively robust to
uncertainty in other parameters including immunization cover-
age and costs other than vaccine acquisition. When the disutility
of a second caregiver is taken into consideration, the cost per
QALY is reduced by 45%.
Ideally, probabilistic sensitivity analysis could be used to
examine the impact of stochastic uncertainty. Nevertheless,
because neither CIs nor distributions are available for many of
the key parameters, the ﬁndings could be misleading. In particu-
lar, the ﬁndings are sensitive to the transient disutility due to
rotavirus, which has been reported in only one study to our
knowledge, and case fatality, which is imprecise because deaths
from rotavirus gastroenteritis are rare in New Zealand. Never-
theless, when the eight key parameters listed above are set at their
extreme values simultaneously (see Table 1), the incremental
cost-utility ratio (ICUR) ranges from -$9755 (dominant) to
+$251,542, indicating that research is required to determine
some of the variables more precisely.
Discussion
This study demonstrates that incorporating PRV into New
Zealand’s immunization schedule for 5 years confers cumulative
health beneﬁts, accompanied by up to 80% decline in the cost of
rotavirus illness as progressively more children are immunized. If
PRV were to remain on the schedule beyond year 5, annual
Table 5 Estimated budget impact in year 5 of an immunization program
with a pentavalent rotavirus vaccine (PRV)*
No PRV
($M)
PRV
($M)
Incr. cost
($M)
Break-even PRV
price per dose ($)
Cost to society 7.07 10.06 2.99 32.39
Cost to health care† 5.27 9.62 4.35 24.40
Cost to government‡ 4.72 9.50 4.78 21.82
*All costs are undiscounted because they are incurred in the same year.
†Ministry of Health, PHARMAC, and direct caregiver costs including hospitalizations, ED
visits, GP visits, and the standard subsidy for oral rehydration therapy.
‡Ministry of Health and PHARMAC only.
Table 6 Cost-effectiveness in year 5 of including a pentavalent rotavirus vaccine in the childhood immunization schedule
Cost per
admission averted
Cost per
case averted
Cost per
death averted
Cost per
life-year gained*
Cost per
QALY gained*
Cost to society $2,509 $305 $3,756,803 $143,097 $46,092
Cost to health care† $3,648 $444 $5,461,436 $208,027 $67,007
Cost to Government‡ $4,015 $488 $6,011,114 $228,964 $73,751
*Annual discount rate 3.5%.
†Ministry of Health, PHARMAC, and direct caregiver costs including hospitalizations, ED visits, GP visits, and the standard subsidy for oral rehydration therapy.
‡Ministry of Health and PHARMAC only.
QALY, quality-adjusted life-year.
Figure 3 Univariate sensitivity analyses on the
cost-effectiveness (cost per quality-adjusted life-
year) of including a pentavalent rotavirus vaccine
in the national immunization schedule (societal
perspective). Parameters that varied the cost-
effectiveness ratio within 15% are excluded.
Parameter ranges can be found in Table 1. CI, con-
ﬁdence interval; ED, Emergency Department; GP,
general practitioner.
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beneﬁts and costs would remain relatively stable for as long as
protective immunity is maintained. Inclusion of PRV on the
childhood immunization schedule would confer important clini-
cal beneﬁts and is moderately cost-effective by year 5.
The estimated overall annual incidence of rotavirus gastroen-
teritis resulting in health-care attendance in New Zealand chil-
dren under 5 years of age of 4655 per 100,000 is similar to that
in Europe [8]. The New Zealand rotavirus hospitalization rate
per 100,000 for this age group of 476 (95% CI; 451, 502)
approximates that of Germany (500), Italy (520), Finland (520),
Spain (650), and the United Kingdom (290–520) but is lower
than that recorded in Australia (750–870) [6–8,42–44]. Recently,
the incidence rate for rotavirus-related hospitalization in New
Zealand was reported as 657 (95% CI; 619, 696) per 100,000 in
children under 3 years of age during 1998 to 2000 [18], which is
similar to the rate of 661 (95% CI; 623, 700) per 100,000 for
this age group in the present study based on a more recent time
period. Based on our ﬁndings, one in ﬁve New Zealand children
will consult a GP or visit a hospital for rotavirus gastroenteritis
by the age of 5 years and one in 43 will be admitted to hospital.
In comparison, by the age of 5 years, the cumulative risk of
hospitalization from rotavirus gastroenteritis among children in
the United States is 1 in 60 [4], 1 in 54 in Europe [5], 1 in 44 in
the United Kingdom [21], and 1 in 27 in Australia [6].
The annual cost of rotavirus gastroenteritis from a societal
perspective in 2009, excluding home care cases not seeking
medical advice, is estimated at $7.07 million, or $22.17 per child
younger than 5 years of age. An Australian study [7], which also
excluded home care cases, estimated the annual cost of rotavirus
disease in children under 5 years of age as $A26 million at 1998
prices, which corresponds to $NZ7.5 million when adjusted for
population differences, price inﬂation, and purchasing power
parity. This level of agreement provides some external validation
of our ﬁndings, although there are differences in both incidence
rates and study methodologies. In the Australian study, the
admission rate was based on a limited number of centers,
whereas in the current study, it was estimated from national
hospitalization rates. In addition to incidence rates, there are
differences between the two countries in primary care access,
referral patterns, disease management, hospitalization policies,
and unit costs. In contrast to New Zealand, the societal cost of
rotavirus gastroenteritis for children younger than 5 years of age
in four European countries (Belgium, France, The Netherlands,
and the United Kingdom) is about twofold higher at €23 per
child and is similar across all four countries [11]. The difference
is partly accounted for by proportionally higher indirect costs
(caregiver income) for women in Europe compared with New
Zealand.
In a recent US study of 548 children hospitalized with rotavi-
rus gastroenteritis [39], the mean length of stay was 2.2 days,
which is comparable to the New Zealand data (1.9 days) [18]
and the mean lost income per family was $US448.77. Although
they cannot be applied directly to New Zealand, costs attribut-
able to caregiver work loss account for most (80%) of the indi-
rect costs in the United States, amounting to a mean of 40 hours
work loss per child hospitalized with rotavirus illness. This ﬁgure
accounts for caregivers who were working full time or part time
or who were not employed. About half this cost occurred during
hospitalization. In our study, indirect costs based on assumptions
about work loss taken from Britain [32] contributed just 25% of
the total cost.
The cost-effectiveness of including PRV in the immunization
schedule is sensitive to the rotavirus incidence rate and the unit
price of PRV as expected. It is also sensitive to caregiver loss of
income and the transient decline in the quality of life experienced
by the child. Speciﬁc New Zealand research is needed on the
incidence of GP and ED cases and the income loss and disutility
associated with caring for children with rotavirus disease. The
incremental societal cost of immunization in our study is prob-
ably overestimated and the break-even price may be underesti-
mated because the model does not take into account nosocomial
infections, emerging evidence of herd immunity contributing to
vaccine effectiveness, or loss of income due to home care cases
[45–47].
Our ﬁndings may be compared to other studies, some of
which have been reviewed recently [48]. Carlin and colleagues in
Australia concluded that the net cost per hospitalization avoided
was $A394 from a societal perspective and $A1023 from a
health-care perspective [49]. These ﬁgures are much lower than
ours, partly because the Australian study assumed a vaccine unit
price of $A30 compared to $NZ50 in our base-case analysis.
A more recent study in Hong Kong, like ours, simulated
successive vaccination of all newborns each year for 5 years and
assumed no fatalities. It concluded that, from a Government
perspective, PRV would be cost saving in this setting if it costs
less than $US40–92 to immunize a child fully [50]. This may be
compared with $NZ24.40 per dose (about $US40 per three-dose
immunization series) from a Government perspective in our
study. In a US study, at a vaccine price of $US62.50 per dose,
vaccination would cost $US138 per case avoided and $US3024
per serious case avoided from a societal perspective. Based on a
very low case fatality, the cost was almost $US200,000 per
life-year saved [51]. Nevertheless, because of inconsistent meth-
odologies and vaccine prices across studies, it is difﬁcult to draw
any ﬁrm conclusions about our ﬁndings in relation to those of
other studies. The cost-effectiveness of routine immunization
with PRV is likely to be much better in developing countries with
relatively high mortality from rotavirus infection than in indus-
trialized countries, including New Zealand.
Recent modeling studies on the cost-effectiveness of rotavirus
vaccination have provided a wide range of conclusions depend-
ing on the country setting, the type of economic model and
the input assumptions and parameters. We estimated cost-
effectiveness ratios for year 5 of an immunization program for
successive birth cohorts in a static equilibrium model. This con-
trasts with the more traditional Markov model used by other
researchers, which follows a single birth cohort for a deﬁned
period of years or a lifetime [28,29,32,50,52]. In Australia, PRV
was found cost saving from a societal perspective when the
disutility of a child and two caregivers (based on the same Cana-
dian study as we used [31]) was included [29]. When only one
caregiver was included, the cost per QALY from a health-care
perspective was higher than that in our study ($A67,681 vs.
$NZ44,092) at a slightly higher unit acquisition cost ($A60 vs.
$NZ50) and coverage (90% vs. 85%). A study from England
and Wales concluded that PRV would not be cost-effective to the
health-care provider [32]. This study had similar hospital admis-
sion rates but a somewhat higher unit vaccine price (£25 vs.
$NZ50 = £18.65), which would increase the cost per QALY;
however, it also included disutility for two caregivers, which will
reduce it.
The main health beneﬁt of rotavirus immunization in New
Zealand and other developed countries is avoidance of the tran-
sient morbidity associated with episodes of severe gastroenteritis,
and the main limitation of our study and others is the scanty
information about the disutility associated with rotavirus infec-
tion. We and others [29,32] utilized the ﬁndings of a recent
Canadian study which estimated the disutility of gastroenteritis
presenting to a GP at 8% for a child and 7% for a caregiver using
standard, well-validated methodologies [31]. Given the sensitiv-
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ity of the cost per QALY (ICUR) to this parameter, further
research is needed in a range of settings. In developing countries,
case fatality ratios will have a much greater inﬂuence on the
ICUR.
Another important limitation is that, because local data are
lacking, incidence rates for GP consultations were estimated
from the ratio of GP cases to hospitalizations from recent studies
in Britain and Australia. This ratio differs more than twofold
between Australia [7] and Britain [21], and it also varies widely
across continental Europe [8]. As local data are unavailable, we
utilized UK data on caregiver work loss because this is culturally
more appropriate to New Zealand than continental European
countries in which work loss was estimated [22]. The sensitivity
analysis (Fig. 3) and comparison of the ICUR from the societal
perspective (where work loss is included) with the health-care
perspective (where it is excluded) show that this parameter is
moderately important. We also assumed immediate uptake of the
immunization program, which is unrealistic. Gradual uptake
over say 5 years would reduce the rate at which costs are incurred
and health beneﬁts are achieved in parallel, but would have little
inﬂuence on the cost-effectiveness ratios, which are insensitive to
coverage.
In most respects, our analysis is conservative. Transmission of
vaccine strains and resulting potential herd immunity could also
be important, as rotavirus is transmitted by infants and children
within families, day care and health-care settings [53–55]. Pre-
liminary data from the United States show that 2 years after the
introduction of PRV into the immunization schedule, the reduc-
tion in severe rotavirus disease appears to approximate that seen
in the phase III efﬁcacy trials despite immunization rates being
lower than for other vaccines because of time limit constraints
upon vaccine administration [46,47,56,57]. Moreover, there
have also been reductions in rotavirus disease in older and unim-
munized age groups [46,47]. Because of lack of information,
our analysis excluded follow-up telephone calls with GPs, labo-
ratory tests ordered by some GPs, community laboratory tests,
complementary therapies, extra diapers, special foods, and over-
the-counter and complementary medications. Community phar-
maceuticals such as antibiotics and antidiarrheals were excluded
from the analysis; however, although these can cost almost as
much as GP consultations [58], they would not add substantially
to the total cost of illness in New Zealand preschool children
because GP consultations comprise only 7.5% of the total cost
(Table 3).
Cases of rotavirus gastroenteritis that are not brought to
medical attention were excluded because the incidence rate,
resource consumption, disutility and work loss, and the propor-
tions of acute gastroenteritis cases that are due to rotavirus are
unknown. Two recent population-based studies have estimated
the incidence of home care cases as three- to fourfold higher than
medical consultations [5,59]. The cost-effectiveness ratios for
PRV would be improved by including home caregiver disutility,
loss of income, over-the-counter medications such as antipyretics
and oral rehydration therapy, and additional diapers.
Our study did not consider the impact of PRV upon nosoco-
mial rotavirus gastroenteritis because there are no reliable New
Zealand data available. Nevertheless, the burden of nosocomial
rotavirus disease is likely to be seriously underestimated. It has
been suggested that as many as 25% of rotavirus-coded cases
collected from hospital discharge data might be due to health-
care associated rotavirus infections [45]. We excluded these cases
by counting only those with a primary diagnosis of acute gastro-
enteritis, even though such infections could add as much as 50%
to the annual hospital cost of rotavirus diarrhea by prolonging
hospital stay [60]. In addition, during such outbreaks, students
and hospital staff can become ill and unable to perform their
duties. Control of rotavirus infection in a hospital setting has
been shown to be extremely difﬁcult despite good hygiene prac-
tices, but a vaccine could reduce this burden considerably. Impor-
tantly, PRV immunization will greatly attenuate winter/spring
epidemics of rotavirus disease, which place an additional burden
on both primary and hospital health-care services by coinciding
with annual peaks in respiratory virus activity.
There are no formal benchmarks for New Zealand’s willing-
ness to pay for novel vaccines. A cost per QALY of $46,092
($US26,774), although modest by international standards [61]
and lower than the value that informed a previous funding deci-
sion for meningococcal type B vaccination during an epidemic in
New Zealand, is higher than that informing most historic
funding decisions for general pharmaceuticals [62]. Ultimately,
some value judgment is required concerning society’s willingness
to pay to reduce the high incidence of distressing severe gastro-
enteritis in preschool children, compared with other health-care
funding priorities, most of which have never been subjected to
detailed economic analysis.
Source of ﬁnancial support: Merck & Co., Inc. partially funded this study
but had no role in the study design, in the analysis and interpretation of
data, in the writing of the report, or in the decision to submit the article for
publication.
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